ACTICCA-1
17 Dec 2020
Trial Summary
ACTICCA-1 is a clinical research study for people who have a cancer of the biliary tract (cancer of the gall bladder or bile duct, also known as cholangiocarcinoma in medical terms) which has been removed in an operation.
Acronym:
ACTICCA-1
ACTRN/NCT /ethics:
ACTRN12615001283561
Scientific title:
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)
Sponsor / Cooperative group:
Universitsklinikum Hamburg-Eppendorf
Trial & Patient Characteristics
| Cancer Type | Other |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Gall Bladder |
| Cancer Stage | All stages |
| Anticipated Start Date | 2014-04-01 |
| Anticipated End Date | 2022-04-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |